Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (589)	12/18/2003 11:34:06 AM
From: nigel bates	Respond to of 1022

XOMA continues to play on strength Almost tempting at this level ? (If they didn't keep taking hospital passes from MLNM).

To: scaram(o)uche who wrote (589)	12/18/2003 11:41:10 AM
From: keokalani'nui	Read Replies (1) \| Respond to of 1022

These 25% or 30% deals are great. Yeah. That's why, from the other side, I'm scratching my head. In a future bind over economics to entice the eventual marketer? Maybe the whole thing goes back to the original bury-the-hatchet phage license. OTOH, years ago when I amateurishly tried to noodle the prospects for a catlytic Mab TPO agonist it did dawn on me how nice it would be to use some else's money for the program.